MTD vs ZYME · P/E 27, rev $3.87B vs rev $76.3M
Mettler-Toledo International Inc (MTD) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Mettler-Toledo International Inc (MTD) is a diagnostics & research company listed on NYSE.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported MTD revenue for 2024-12-31 was $3.87B. Net income was $863.1M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. MTD currently screens at market cap $23.20B and trailing P/E 26.9.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
MTD currently screens at market cap $23.20B and trailing P/E 26.9. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the MTD and ZYME stock pages for the full models.
Not investment advice.